Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for retinitis pigmentosa 50 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for retinitis pigmentosa 50 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
bestrophin 1 (BEST1) — BEST1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 8D1I · 1.82 Å · ligand 1,2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE (MC3). Experimental structure, not a prediction.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractStudies of underlying molecular mechanisms of retinitis pigmentosa in experimental model and clinicsU.S. IsmailovaAcademician Abdulla Garayev Institute of Physiology, Azerbaijan National Academy of Sciences, 78 Sharifzadeh Str., Baku AZ1100, AzerbaijanFor correspondence: [email protected]
https://doi.org/10.29228/jlsb.51AbstractRetinitis pigmentosa(RP)was known as pigmentation retinitis even. RP is a group of hereditary eye diseases that cause irreversible visual impairment due to progressive loss of function of retinal pigment epithelial cells and progressive apoptosis of photoreceptors. Because of its heterogeneity in phenotype and heredity and complex pathogenesis, there is currently no single effective treatment. This article mainly elaborates on the progress in the treatment of retinitis pigmentosa in recent years.
https://doi.org/10.3980/j.issn.1672-5123.2020.4.10Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
